user

Incidence of Inhibitors in Previously Untreated Patients with Severe Hemophilia a Treated with Plasma-Derived Vs. Recombinant Factor VIII Concentrates: A Systematic Review and Meta-Analyses

被引：0
|
作者：
Prezotti, Alessandra N. L. [1 ,2 ]
Villaca, Paula Ribeiro [3 ]
Rocha, Debora M. C. [2 ]
Orletti, Maria P. S. V. [2 ]
Lourenco, Christiane [2 ]
Yamaguti Hayakawa, Gabriela G. [1 ,4 ]
Ozelo, Margareth C. [1 ,4 ]
机构：
[1] Univ Estadual Campinas, Sch Med Sci, Dept Internal Med, UNICAMP, Campinas, SP, Brazil
[2] HEMOES, Hemoctr Espirito Santo, Vitoria, ES, Brazil
[3] Univ Sao Paulo, Fac Med, Hosp Clin, Sao Paulo, SP, Brazil
[4] Univ Estadual Campinas, Hemoctr UNICAMP, Campinas, SP, Brazil
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-171028
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Influence of the type of factor VIII concentrates on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A: further clarifications on the cohorts' follow-up
    Goudemand, J
    Rothschild, C
    Laurian, Y
    Calvez, T
    BLOOD, 2006, 107 (09) : 3810 - 3810
  • [22] INCIDENCE OF INHIBITORS IN PATIENTS WITH SEVERE AND MODERATE HEMOPHILIA-A TREATED WITH FACTOR-VIII CONCENTRATES
    SCHWARZINGER, I
    PABINGER, I
    KORNINGER, C
    HASCHKE, F
    KUNDI, M
    NIESSNER, H
    LECHNER, K
    AMERICAN JOURNAL OF HEMATOLOGY, 1987, 24 (03) : 241 - 245
  • [23] Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates
    Haase, M
    BLOOD, 2002, 100 (12) : 4242 - 4242
  • [24] Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates
    Roth, DA
    Kessler, CM
    Pasi, KJ
    Rup, B
    Courter, SG
    Tubridy, KL
    BLOOD, 2001, 98 (13) : 3600 - 3606
  • [25] Plasma-derived factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A: report of the FranceCoag Network
    Goudemand, J.
    Rothschild, C.
    d'Oiron, R.
    Demiguel, V
    Dalibard, V
    Micheau, M.
    Lutz, P.
    Gruel, Y.
    Vinciguerra, C.
    Chambost, H.
    Calvez, T.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 148 - 148
  • [26] High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis
    Messori, Andrea
    Peyvandi, Flora
    Trippoli, Sabrina
    Palla, Roberta
    Rosendaal, Frits R.
    Mannucci, Pier Mannuccio
    BLOOD TRANSFUSION, 2018, 16 (02) : 215 - 220
  • [27] US Economic Impact of Recombinant FVIII Vs Plasma-Derived FVIII/VWF in Previously Untreated Hemophilia a Patients
    Sidonio, Robert F.
    Runken, M. Chris
    O'Day, Ken
    Meyer, Kellie
    Spears, Jeffrey
    BLOOD, 2017, 130
  • [28] Pharmacokinetics (PK) of recombinant and plasma-derived factor VIII (FVIII) products in pediatric patients with severe hemophilia A
    Steele, M.
    Chan, A.
    Nagel, K.
    HAEMOPHILIA, 2012, 18 : 35 - 35
  • [29] Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011
    Collins, Peter W.
    Palmer, Benedict P.
    Chalmers, Elizabeth A.
    Hart, Daniel P.
    Liesner, Ri
    Rangarajan, Savita
    Talks, Katherine
    Williams, Michael
    Hay, Charles R. M.
    BLOOD, 2014, 124 (23) : 3389 - 3397
  • [30] Further comments on "High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis"
    Messori, Andrea
    Peyvandi, Flora
    Trippolit, Sabrina
    Palla, Roberta
    Rosendaal, Frits R.
    Mannucci, Pier Mannuccio
    BLOOD TRANSFUSION, 2019, 17 (01) : 86 - 86
12345